INSYS - erfolgreich in der Krebsforschung? - 500 Beiträge pro Seite
eröffnet am 12.05.11 14:43:14 von
neuester Beitrag 31.08.11 19:06:34 von
neuester Beitrag 31.08.11 19:06:34 von
Beiträge: 10
ID: 1.166.137
ID: 1.166.137
Aufrufe heute: 0
Gesamt: 1.018
Gesamt: 1.018
Aktive User: 0
ISIN: US45824V2097 · WKN: A1JC8P
0,2647
EUR
+1,34 %
+0,0035 EUR
Letzter Kurs 19.06.19 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 | |
| 1,7000 | +13,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7400 | -9,87 | |
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Feedback
Insys Therapeutics, ISIN: US45824V1008, wird in den USA unter dem Symbol NEOL gehandelt und hat die ehemalige Neopharm Inc. übernommen. Näheres auf deren Website http://www.insysrx.com auf der sich das Unternehmen vorstellt.
Die Aktie wird inzwischen auch in FFM gehandelt.
Die Aktie wird inzwischen auch in FFM gehandelt.
Company News
NEOL NEOL
Insys Therapeutics, Inc. Other OTC
Back to Headlines | Print Version | ShareThis
Insys Announces NDA Acceptance of its Fentanyl SL Spray
PHOENIX--(BUSINESS WIRE)-- Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL.PK) today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.
“We are excited to have the FDA accept our filing, and we look forward to building a commercial infrastructure to launch this product for patients suffering from breakthrough cancer pain,” said Insys CEO Michael Babich. “The proprietary sublingual delivery system will provide us an opportunity to deliver pain relief to cancer patients who suffer from excruciating acute pain episodes that overcome the analgesia of chronic opioid medications.”
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, Insys’ plans to build a sales force, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
Source: Insys Therapeutics, Inc.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
NEOL NEOL
Insys Therapeutics, Inc. Other OTC
Back to Headlines | Print Version | ShareThis
Insys Announces NDA Acceptance of its Fentanyl SL Spray
PHOENIX--(BUSINESS WIRE)-- Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL.PK) today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.
“We are excited to have the FDA accept our filing, and we look forward to building a commercial infrastructure to launch this product for patients suffering from breakthrough cancer pain,” said Insys CEO Michael Babich. “The proprietary sublingual delivery system will provide us an opportunity to deliver pain relief to cancer patients who suffer from excruciating acute pain episodes that overcome the analgesia of chronic opioid medications.”
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, Insys’ plans to build a sales force, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
Source: Insys Therapeutics, Inc.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
zur Zeit in NY ein Plus von rund 21 %
heute ein Start mit 0,35 USD ???
Trading Spotlight
Company News
NEOL NEOL
Insys Therapeutics, Inc. Other OTC
Back to Headlines | Print Version | ShareThis
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
PHOENIX--(BUSINESS WIRE)-- INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL&index=1&md5=a10ed7f743f5fb10e1362cc0145f5d35">NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Preion Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
Source: INSYS Therapeutics, Inc.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
NEOL NEOL
Insys Therapeutics, Inc. Other OTC
Back to Headlines | Print Version | ShareThis
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
PHOENIX--(BUSINESS WIRE)-- INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL&index=1&md5=a10ed7f743f5fb10e1362cc0145f5d35">NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Preion Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
Source: INSYS Therapeutics, Inc.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Split am 18.7.2011 mit 61 : 1 
Jetzt mit neuer WKN A1JC8P und Isin US45824V2097
in D wird z.Zt. nur in Frankfurt gehandelt
In den USA ist aus NEOL nun NEOLD geworden.
Jetzt mit neuer WKN A1JC8P und Isin US45824V2097
in D wird z.Zt. nur in Frankfurt gehandelt
In den USA ist aus NEOL nun NEOLD geworden.
erstaunliche Differenz 
Gestern in den USA ein Plus von 37,06 % bei 13,98 USD,
heute in Frankfurt minus 29 % bei 6,65 Euro.
Wie geht das zusammen?
Gestern in den USA ein Plus von 37,06 % bei 13,98 USD,
heute in Frankfurt minus 29 % bei 6,65 Euro.
Wie geht das zusammen?
plus 33 % in NY. was ist da los?
Antwort auf Beitrag Nr.: 42.027.737 von Nissie am 31.08.11 18:54:26Durch den Split hat Neol jetzt weniger als 1 million aktien im umlauf da sind kurssprünge mit ein paar aktien möglich .
Würde die Aktie dennoch nicht anfassen mit 0 cash bestand und über 45 million$ schulden .
Würde die Aktie dennoch nicht anfassen mit 0 cash bestand und über 45 million$ schulden .
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,68 | |
| +0,88 | |
| -2,21 | |
| -4,33 | |
| +0,43 | |
| +8,87 | |
| +0,87 | |
| -0,48 | |
| -0,97 | |
| -7,10 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 206 | ||
| 140 | ||
| 123 | ||
| 76 | ||
| 36 | ||
| 34 | ||
| 30 | ||
| 30 | ||
| 29 | ||
| 29 |
